TABLE 3-11 R&M EXPENSES FOR FY 2023-24 .......................................................................................... 76 TABLE 3-12 NORMATIVE R&M EXPENSES FOR FY 2023-24 ................................................................ 76 TABLE 3-13 COMPUTED A&G EXPENSES FOR FY 2023-24 .................................................................. 77 TABLE 3-14 NORMATIVE A&G EXPENSES FOR FY 2023-24 ................................................................. 77 TABLE 3-15 SMART METERING OPEX FOR FY 2023-24 ......................................................................... 78 TABLE 3-16 OPERATION & MAINTENANCE EXPENSES FOR FY 2023-24 (IN RS.cr。)...............................................................................................................................................................................................................................................................................cr。)........................................................................................................... 79表3-18 FY 2023-24(以卢比为单位cr。)..................................................................................... 80 TABLE 3-19 CAPITAL INVESTMENT IN FY 2023-24 (IN RS.cr。)......................................................................................................................................................... 81表3-20消费者捐款,资本赠款和补贴2023-24(以卢比为单位CR) ................................................................................................................................................................ 81 TABLE 3-20 FINANCING OF THE CAPITAL INVESTMENTS IN FY 2023-24 (IN RS.cr。)............... 82 TABLE 3-21 ALLOWABLE INTEREST ON LONG TERM LOAN FOR FY 2023-24 (IN RS.cr。)............ 82表3-22关于2023-24财年保证金的利息(以卢比为单位cr。)cr。)cr。)........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 83 TABLE 3-24 INTEREST ON WORKING CAPITAL FOR FY 2023-24 (IN RS................................. 84 TABLE 3-25 INTEREST AND FINANCE CHARGES FOR FY 2023-24 (IN RS.cr。)........................... 85 TABLE 3-26 GROSS ALLOWABLE DEPRECIATION FOR FY 2023-24 (IN RS.cr。)A部分...............................................................................................................................................................................................................................................................................................................................................................................................cr。)B部分.......... 87表3-28 FY 2023-24的净允许折旧(以卢比为单位cr。)................................ 88 TABLE 3-29 ALLOWABLE PROVISION FOR BAD AND DOUBTFUL DEBTS FOR FY 2023-24 (IN RS.cr。)...................................................................................................................................................................... 88 TABLE 3-30 RETURN ON EQUITY (ROE) FOR FY 2023-24 (IN RS.cr。)............................................. 89 TABLE 3-31 NON- TARIFF INCOME FOR FY 2023-24 (IN RS.cr。)...................................................... 89 TABLE 3-32 CONSOLIDATED DETAILS OF APPROVED GOUP SUBSIDY .......................................... 90 TABLE 3-33 GOUP SUBSIDY FOR FY 2023-24 (IN RS.cr。).................................................................. 90 TABLE 3-34 ANNUAL PERFORMANCE REVIEW (APR) FOR FY 2023-24 (IN RS.cr。)cr。)............ 118 TABLE 4-15 EMPLOYEE EXPENSES FOR FY 2024-25 (IN RS.cr。)cr。)cr。)................................................... 118 TABLE 4-16 COMPUTATION OF R&M EXPENSES FOR FY 2024-25 (IN RS.......................... 118 TABLE 4-17 R&M EXPENSES FOR FY 2024-25 (IN RS................................................................. 119 TABLE 4-18 COMPUTED A&G EXPENSES FOR FY 2024-25 (IN RS.cr。)........................................ 119 TABLE 4-19 NET A&G EXPENSES FOR FY 2024-25 (IN RS.cr。)....................................................... 119 TABLE 4-20 SMART METERING OPEX FOR FY 2024-25 ....................................................................... 122 TABLE 4-21 OPERATION & MAINTENANCE EXPENSES PROJECTED FOR FY 2024-25 (IN RS.cr。)............................................................................................................................................................................ 122 TABLE 4-22 PROPOSED CAPITAL EXPENDITURE DETAILS FOR FY 2024-25 (IN RS.cr。)...... 124
Joint CQSE and CASTS Seminar 2020 December 25, Friday TIME Dec. 25, 2020, 2:30~3:30pm TITLE Beyond the Photonics, Quantum Information Technology & Industry Emerge and Start Revolution & Evolution SPEAKER Murphy Lin Director, Photonics Industry & Technology Development Association PLACE Rm104, Chin-Pao Yang Lecture Hall, CCMS & New Physics Building, NTU Outline: Introduction of Photonics Industry & Technology Development Association, PIDA光的历史视图,从光子,光波,电磁波,量子,波颗粒二元性到波功能,以及经典的量子和现代量子。为什么量子技术是下一个时代?量子技术概述和应用 - 量子传感,量子通信,量子计算。什么是量子外围设备?光子源,光子检测器,量子记忆和中继器等。霸权在达到“量子至上”的作用是什么?传记简介:林颖毅墨菲林
通过结合讲座和现场 HVAC 实验室的实践经验,学生还将了解安全程序、制冷设备安装和维修工具的正确使用方法以及制冷剂充注和回收技术。在第二年,学生将专注于分析 HVAC 单元中的机械和电气问题,深入了解压缩机、计量装置、系统充注、制冷剂回收、电机类型、设备安装以及 HVAC 系统特有的故障排除。此外,二年级学生将有机会在课堂外参与实际项目。对于那些选择完成第三年课程的学生,他们将获得宝贵的实习或工作见习机会。成功完成两年制课程后,学生有机会通过 Ivy Tech 社区学院获得二十一 (21) 个大学学分,并获得技术核心证书。学生还可以获得以下认证:EPA 608、EPA 609 OSHA 10 和 Mr. Vest 颁发的职场准备认证。
目标 - 开发和实施先进制造技术,以确保国防物资的可用性和可负担性,具体方法如下:• 尽早确定将新技术插入现有/未来系统 • 确定与新技术应用相关的制造风险/未知因素 • 投资于先进制造能力的研究、开发和实施
“辅助服务”指 (1) 持牌发电厂、持牌发电厂/海水淡化厂或将其场所连接到输电系统或配电系统的其他人士可能需要不时提供的与该输电系统或整个系统的安全性和稳定性有关的服务;及 (2) 在 (i) 持牌输电系统运营商或持牌配电系统运营商与任何人士之间的协议或 (ii) 持牌发电厂或持牌发电厂/海水淡化厂与 PWP 之间的协议中规定的服务;
神经内分泌肿瘤 (NET) 有时也称为类癌肿瘤,是一组源自内分泌(激素)和神经系统细胞的异质性恶性肿瘤(癌症)。根据美国国家癌症研究所的监测、流行病学和最终结果 (SEER) 18 登记处的数据,估计神经内分泌肿瘤 20 年总患病率为 171,321 例,每年年龄调整后的发病率为每 100,000 人 6.98 例(Dasari 2017)。一项基于人群的研究发现,1973 年至 2012 年间,神经内分泌肿瘤的发病率增加了 6.4 倍(Dasari 2017)。NET 在高龄患者中更常见,65 岁或以上患者的发病率为每 100,000 人 25 例。约 61.0% 的 NET 源自胃肠道或胰腺( Lawrence 2011 ),因此这些肿瘤被称为胃肠胰 NET(GEP-NET)。原发性 NET 的其他部位包括肺、甲状腺、卵巢、宫颈、垂体和肾上腺( Hallet 2015 )。
